Cranioplasty Cognitive Outcome Study

NCT03791996 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-10-17

No results posted yet for this study

Summary

This will be a multicenter prospective randomized study of adult patients with an acquired skull defect as a result of craniectomy and considered suitable for cranioplasty, i.e. reconstruction of the skull defect, at all seven Hong Kong Hospital Authority neurosurgical units. Patients that underwent their primary craniectomy operation at any of the Hospital Authority neurosurgery centers from the 1st March 2019 and considered suitable for cranioplasty will be included in this study. Those who underwent their primary craniectomy before 1st March 2019 or at an institution other than the aforementioned neurosurgical units will be excluded. Data from clinical records, operation notes, medication-dispensing records, laboratory records and radiological reports will be collected.

30 adult patients with craniectomy will be recruited and randomized into two groups: "early" cranioplasty, i.e. performed within 3 months of craniectomy, and "late", i.e. cranioplasty performed more than 3 months after the operation. The aim of the study is to determine whether early cranioplasty can improve on patient's cognitive performance compared to those who undergo the procedure after 3 months.

Conditions

Interventions

PROCEDURE

"Early" cranioplasty

Subjects undergoing cranioplasty beyond 3 months after craniectomy.

Sponsors & Collaborators

  • The Queen Elizabeth Hospital

    collaborator OTHER
  • Queen Mary Hospital, Hong Kong

    collaborator OTHER
  • Prince of Wales Hospital, Shatin, Hong Kong

    collaborator OTHER
  • Princess Margaret Hospital, Canada

    collaborator OTHER
  • Tuen Mun Hospital

    collaborator OTHER_GOV
  • Pamela Youde Nethersole Eastern Hospital

    collaborator OTHER
  • Kwong Wah Hospital

    lead OTHER

Principal Investigators

  • Calvin Mak, MBBS FRCS · Neurosurgery, Queen Elizabeth Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2020-09-01
Completion
2021-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03791996 on ClinicalTrials.gov